Skip to main content

Table 5 Comparison between two subgroups of group A

From: Impact of sustained virologic response in regression of portal hypertension in Egyptian patients with hepatitis C virus-associated cirrhosis and portal hypertension

Variables

(Group I)

(Group II)

Student t-test

N (%)

Mean ± SD

N (%)

Mean ± SD

T-test

p-value

Laboratory values

AST (IU/L)

88.5 ± 51.28

64.25 ± 34.95

−1.650

0.107

ALT (IU/L)

64.04 ± 38.46

43.38 ± 35.29

−1.719

0.094

T. bilirubin (mg/dL)

1.58 ± 0.97

1.63 ± 0.75

0.170

0.866

Serum albumin (g/dL)

3.08 ± 0.4

2.57 ± 0.4

−3.979

< 0.001

INR

1.32 ± 0.17

1.4 ± 0.22

1.320

0.195

Platelet count × 103/mm

89.46 ± 17.89

67.06 ± 11.49

−4.822

< 0.001

Noninvasive serum markers

Child-Pugh score

7.08 ± 1.25

8.56 ± 0.63

4.371

< 0.001

APRI score

2.86 ± 2.05

2.63 ± 1.37

−0.390

0.699

AAR

1.9 ± 2.65

1.74 ± 0.65

−0.230

0.819

PC/SD ratio

609 ± 156

398 ± 75

−5.694

< 0.001

FIB-4 index

8.07 ± 6.34

8.38 ± 3.39

0.179

0.859

King’s score

80.03 ± 53.02

72.42 ± 38.4

−0.493

0.625

Lok index

2.99 ± 3.61

3.42 ± 1.23

0.462

0.647

Abdominal US

Spleen diameter (cm)

16.91 ± 0.82

14.96 ± 1.4

t = 5.541

< 0.001

Portal and hepatic veins duplex

PV diameter (mm)

13.94 ± 1.04

15.13 ± 0.53

t = 4.755

< 0.001

PV velocity (cm/s)

13.44 ± 1.84

10.94 ± 1.01

t = −5.522

< 0.001

HV waveform

Monophasic

1 (4.2%)

14 (87.5%)

Fisher’s exact test

0.006

Biphasic

12 (50%)

2 (12.5%)

Triphasic

11 (45.8%)

0 (0%)

Collaterals

Yes

1 (16.67%)

5 (83.33%)

Fisher’s exact test

0.029

No

23 (67.65%)

11 (32.35%)